CTLA-4 blockade: therapeutic potential in cancer treatments

References

• RibasACamachoLHLopez-BeresteinGAntitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206J Clin Oncol2005238968897716204013
   PubMed Web of Science ®Google Scholar
• KadowakiNHoSAntonenkoSSubsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigensJ Exp Med200119486386911561001
   PubMed Web of Science ®Google Scholar
• KriegAMCpG motifs in bacterial DNA and their immune effectsAnnu Rev Immunol20022070976011861616
   PubMed Web of Science ®Google Scholar
• KriegAMTherapeutic potential of Toll-like receptor 9 activationNat Rev Drug Discov2006547148416763660
   PubMed Web of Science ®Google Scholar
• TarhiniAAKirkwoodJMAMKEarly development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancersExpert Opin Drug Discov200945587603
   PubMed Web of Science ®Google Scholar
• KhattriRAugerJAGriffinMDLymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responsesJ Immunol19991625784579110229811
   PubMed Web of Science ®Google Scholar
• TivolEABorrielloFSchweitzerANLoss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4Immunity199535415477584144
   PubMed Web of Science ®Google Scholar
• WaterhousePPenningerJMTimmsELymphoproliferative disorders with early lethality in mice deficient in Ctla-4Science19952709859887481803
   PubMed Web of Science ®Google Scholar
• LenschowDJWalunasTLBluestoneJACD28/B7 system of T-cell costimulationAnnu Rev Immunol1996142332588717514
   PubMed Web of Science ®Google Scholar
• KrummelMFAllisonJPCD28 and CTLA-4 have opposing effects on the response of T-cells to stimulationJ Exp Med19951824594657543139
   PubMed Web of Science ®Google Scholar
• MakerAVPhanGQAttiaPTumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II studyAnn Surg Oncol2005121005101616283570
   PubMed Web of Science ®Google Scholar
• LinsleyPSGreeneJLBradyWHuman B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptorsImmunity199417938017534620
   PubMed Web of Science ®Google Scholar
• PatersonAMVanguriVKSharpeAHSnapShot: B7/CD28 costimulationCell200913797497419490900
   PubMed Web of Science ®Google Scholar
• LinsleyPSBradyWUrnesMCTLA-4 is a second receptor for the B cell activation antigen B7J Exp Med19911745615691714933
   PubMed Web of Science ®Google Scholar
• AlegreMLShielsHThompsonCBExpression and function of CTLA-4 in Th1 and Th2 cellsJ Immunol1998161334733569759851
   PubMed Web of Science ®Google Scholar
• McCoyKDLe GrosGThe role of CTLA-4 in the regulation of T-cell immune responsesImmunol Cell Biol19997711010101680
   PubMed Web of Science ®Google Scholar
• EgenJGAllisonJPCytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strengthImmunity200216233511825563
   PubMed Web of Science ®Google Scholar
• EgenJGKuhnsMSAllisonJPCTLA-4: new insights into its biological function and use in tumor immunotherapyNat Immunol2002361161812087419
   PubMed Web of Science ®Google Scholar
• KwonEDHurwitzAAFosterBAManipulation of T-cell costimulatory and inhibitory signals for immunotherapy of prostate cancerProc Natl Acad Sci U S A199794809981039223321
   PubMed Web of Science ®Google Scholar
• LeachDRKrummelMFAllisonJPEnhancement of antitumor immunity by CTLA-4 blockadeScience1996271173417368596936
   PubMed Web of Science ®Google Scholar
• KwonEDFosterBAHurwitzAAElimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA–4) blockade immunotherapyProc Natl Acad Sci U S A199996150741507910611340
   PubMed Web of Science ®Google Scholar
• MakerAVAttiaPRosenbergSAAnalysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockadeJ Immunol20051757746775416301685
   PubMed Web of Science ®Google Scholar
• CanniffPCDonovanCBBurkwitJJCP-675,205 anti-CTLA4 antibody clinical candidate enhances IL-2 production in cancer patient T-cells in vitro regardless of tumor type or stage of disease [poster], [abstract 709]Orlando, FL95th Annual Meeting of the American Association for Cancer Research2004
   Google Scholar
• HansonDCCanniffPCPrimianoMJPreclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206 [poster], [abstract 3802]Orlando, FL95th Annual Meeting of the American Association for Cancer Research2004
   Google Scholar
• CamachoLHRibasAGlaspyJAPhase I clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients with advanced solid malignancies [oral presentation] [abstract 2005]J Clin Oncol20042214s (Suppl; abstract 2505).
   Web of Science ®Google Scholar
• MorellATerryWDWaldmannTAMetabolic properties of IgG subclasses in manJ Clin Invest1970496736805443170
   PubMed Web of Science ®Google Scholar
• RibasABozonVALopez-BeresteinGPhase I trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanomaJ Clin Oncol200523Suppl716s (abstr 7524).
   Google Scholar
• LoboEDHansenRJBalthasarJPAntibody pharmacokinetics and pharmacodynamicsJ Pharm Sci2004932645266815389672
   PubMed Web of Science ®Google Scholar
• WangEKangDWangCRelationship between pharmacokinetics and safety of tremelimumab in patients with melanomaJ Clin Oncol200927Suppl15s (abstr 3049).
   Google Scholar
• RibasAAntoniaSSosmanJResults of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma [oral]J Clin Oncol200725Suppl18S (abstr 3000).
   Google Scholar
• ChungKYGoreIFongLA phase II study of tremelimumab (CP-675,206), an anti-CTLA4 monoclonal antibody, in patients with refractory metastatic colorectal cancer [oral presentation]Boston, MAInternational Society for Biological Therapy of Cancer 22nd Annual Meeting2007
   Google Scholar
• ZatloukalPHeoDSParkKRandomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)J Clin Oncol200927Suppl15s (abstr 8071).
   Google Scholar
• VonderheideRHLoRussoPMKhalilMTremelimumab in combination with exemestane as novel immunotherapy for patients with advanced breast cancerJ Clin Oncol200927Suppl15s (abstr 3034).
   Google Scholar
• GordonMSSteinMShannonPPhase I dose escalation trial of tremelimumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)J Clin Oncol200927Suppl15s (abstr 5115).
   Google Scholar
• SmallEWeinbergVKavanaghBCombination immunotherapy with GM-CSF and ipilimumab (anti-CTLA4 antibody) in patients with metastatic hormone refractory prostate cancer2007 Prostate Cancer Symposium (abstr 49 2007).
   Google Scholar
• SlovinSBeerTHiganoCInitial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC)J Clin Oncol200927Suppl15s (abstr 5138).
   Google Scholar
• Gomez-NavarroJSharmaABozonVDose and schedule selection for the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in patients (pts) with metastatic melanomaJ Clin Oncol200624Suppl460s (abstr 8032).
   Google Scholar
• Gomez-NavarroJAntoniaSSosmanJSurvival of patients (pts) with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in a phase I/II study. [poster]J Clin Oncol200725Suppl18s (abstr 8524).
   Google Scholar
• Comin-AnduixBLeeYJalilJDetailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanomaJ Transl Med200862218452610
   PubMed Web of Science ®Google Scholar
• ReubenJMLeeBNShenDYTherapy with human monoclonal anti-CTLA-4 antibody, CP-675,206, reduces regulatory T-cells and IL-10 production in patients with advanced malignant melanoma (MM) [oral presentation]J Clin Oncol20052316S (Suppl:abstract 7505).
   Web of Science ®Google Scholar
• KirkwoodJMLoriganPHerseyPA phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma [poster and discussion]J Clin Oncol200826Suppl (abstr 9023).
   Google Scholar
• ChungKYDorazioPPavlovDSurvival of patients with refractory metastatic colorectal cancer treated with tremelimumab (CP-675,206), an anti-CTLA4 monoclonal antibody in a phase II study [poster] [abstract 351]Presented at the 2008 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology
   Google Scholar
• RibasAComin-AnduixBJalilJCombination of dendritic cell (DC) vaccination with CTLA4 blockade in patients (pts) with metastatic melanoma: a phase 1 clinical trial [oral] [abstract 2537]San Diego, CAPresented at the American Association for Cancer Research SymposiumApril 12–16, 2008
   Google Scholar
• TarhiniAAMoschosSSSchlesselmanJJPhase II trial of combination biotherapy of high-dose interferon alfa-2b and tremelimumab for recurrent inoperable stage III or stage IV melanomaJ Clin Oncol200826Suppl (abstr 9009).
   Google Scholar
• UnderhillCMillwardMLobbSPhase I dose escalation trial of tremelimumab (CP-675,206) administered in combination with PF-3512676 in patients with melanoma or other advanced cancersJ Clin Oncol200927Suppl15s (abstr 3046).
   Google Scholar
• RibasAHauschildAKeffordRPhase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma [oral]J Clin Oncol200826520Suppl (abstr LBA9011).
   Google Scholar
• WallisNBulanhaguiCDorazioPCSafety of tremelimumab (CP-675,206) in patients (pts) with advanced cancer [poster]J Clin Oncol200826520Suppl (abstr 3040).
   Google Scholar
• StraatsmaBRNusinowitzSYoungTASurveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanomaAm J Ophthalmol200714395896917434437
   PubMed Web of Science ®Google Scholar
• AttiaPPhanGQMakerAVAutoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T lymphocyte antigen-4J Clin Oncol2005236043605316087944
   PubMed Web of Science ®Google Scholar
• SmallEJTchekmedyianNSRiniBIA pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancerClin Cancer Res2007131810181517363537
   PubMed Web of Science ®Google Scholar
• PhanGQYangJCSherryRMCancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanomaProc Natl Acad Sci U S A20031008372837712826605
   PubMed Web of Science ®Google Scholar
• DaiDWuSParkerMModel-based evaluation of ipilimumab dose regiment in patients with advanced melanomaJ Clin Oncol2008520Suppl 26 (abstr 9073).
   Google Scholar
• ThompsonJBermanDSiegalJEffect of prior treatment status on the efficacy and safety of ipilimumab monotherapy in treatment-naive and previously treated patients with advanced melanomaProc Am Soc Clin Oncol200826 (abstr 9055).
   Web of Science ®Google Scholar
• TchekmedyianSGlasbyJKormanAMDX-010 (human anti-CTLA4): a phase I trial in malignant melanomaProc Am Soc Clin Oncol200221 (abstr 56).
   Google Scholar
• HodiFSButlerMObleDAImmunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patientsProc Natl Acad Sci U S A20081053005301018287062
   PubMed Web of Science ®Google Scholar
• HamidODose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging studyJ Clin Oncol200826Suppl (abstr 9025).
   Google Scholar
• HershEWeberJPowderlyJLong-term survival of patients with advanced melanoma treated with ipilimumab with or without dacarbazineJ Clin Oncol200927Suppl15s (abstr 9038).
   Google Scholar
• FischkoffSHershEWeberJDurable responses and long-term progression-free survival observed in a phase ii study of mdx-010 alone or in combination with dacarbazine (dtic) in metastatic melanomaJ Clin Oncol200523Suppl16s (abstr 7525).
   Google Scholar
• BeerTSlovinSHiganoCPhase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC)J Clin Oncol200826Suppl (abstr 5004).
   Google Scholar
• BlansfieldJABeckKETranKCytotoxic T lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancerJ Immunotherapy200528593598
   PubMed Web of Science ®Google Scholar
• YangJCHughesMKammulaUIpilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitisJ Immunotherapy200730825830
   PubMed Web of Science ®Google Scholar
• WeberJSafety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanomaJ Clin Oncol200526Suppl (abstr 9010).
   Google Scholar
• MakerAVYangJCSherryRMIntrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanomaJ Immunotherapy200629455463
   PubMed Web of Science ®Google Scholar
• WolchokJde PrilVLinetteGEfficacy of ipilimumab 10 mg/kg in advanced melanoma patients with good and poor prognostic factorsJ Clin Oncol200927Suppl15s (abstr 9036).
   Google Scholar
• SmylieMFrancisSNeynsBEffect of ipilimumab at 10 mg/kg on disease control in patients (pts) with M1c-stage melanoma in relation to baseline lactate dehydrogenase (LDH) levelsJ Clin Oncol200927Suppl15s (abstr 9041).
   Google Scholar
• O’DaySWeberJLebbeCIpilimumab treatment may be associated with a long-term survival benefit: 18-month survival rate of patients with advanced melnaoma treated with 10 mg/kg ipilimumab in three phase ii clinical trialsJ Clin Oncol200927Suppl15s (abstr 9033).
   Google Scholar
• WeberJSarnaikATarganSPhase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multipeptide vaccine for resected stages IIIC and IV melanomaJ Clin Oncol200927Suppl15s (abstr 9023).
   Google Scholar
• LutzkyJWolchokJHamidOAssociation between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trialsJ Clin Oncol200927Suppl15s (abstr 9034).
   Google Scholar
• ChenBPhillipsJGreenbaumMEfficacy of anti-CTLA-4 anti-body in the SA1N tumor model when combined with dexamethasone98th AACR Annual Meeting, AACR Meeting AbstractsApr 2007: Abstract 2202.
   Google Scholar
• WeberJSafety and efficacy of iplimumab with or without prophylactic budesonide in the treatment-naive and preveiously treated patients with advanced melanomaJ Clin Oncol200826Suppl (abstr 9010).
   Google Scholar
• KornELLiuPYLeeSJMeta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trialsJ Clin Oncol20082652753418235113
   PubMed Web of Science ®Google Scholar
• KornELiuPYLeeSMeta-analysis of phase II cooperative group trials in metastatic stage iv melanoma: determining progression-free and overall survival benchmarks for future phase II trialsJ Clin Oncol20082652753418235113
   PubMed Web of Science ®Google Scholar
• WeberJSHershEMYellinMThe efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma [poster]J Clin Oncol200725Suppl477s (abstr 8523).
   Google Scholar
• WeberJSThe clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodiesMelanoma Res20061637938317013086
   PubMed Web of Science ®Google Scholar
• TatsumiTKiersteadLSRanieriEDisease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T-cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanomaJ Exp Med200219661962812208877
   PubMed Web of Science ®Google Scholar
• TatsumiTHerremCJOlsonWCDisease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinomaCancer Res2003634481448912907621
   PubMed Web of Science ®Google Scholar
• van ElsasAHurwitzAAAllisonJPCombination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentationJ Exp Med199919035536610430624
   PubMed Web of Science ®Google Scholar